In the latest episode of an ongoing saga, ImClone Systems Inc. gained and lost in a retooling of what had been touted as a landmark potential $2 billion deal with Bristol-Myers Squibb Co. for the FDA-stalled colorectal cancer drug Erbitux (cetuximab). (BioWorld Today) Read More
